Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerBilling CodesProprietary Laboratory AnalysesCPT cpt-0630u-blueprint-molecular-subtyping-breast-cancer
    Ask Trek AI about this page

    CPT 0630U: BluePrint Molecular Subtyping Test for Breast Cancer

    CPT code 0630U is a Proprietary Laboratory Analyses (PLA) code that reports the BluePrint® Molecular Subtyping Test by Agendia® Inc., an oncology molecular diagnostic that uses mRNA gene expression profiling by microarray to evaluate 80 genes from formalin–fixed paraffin–embedded (FFPE) breast cancer tissue and generates an index that classifies molecular subtype (for example, luminal, basal, or HER2); service type: laboratory molecular diagnostic testing using microarray-based gene expression profiling; typical site of service: outpatient or hospital-associated clinical laboratory or reference laboratory processing FFPE tumor specimens.

    For related coverage guidance, see recent payer policy updates: Minimal Residual Disease (MRD) Testing for Cancer, Biomarker Testing Mandate, Prenatal (Fetal) Diagnostic Testing.

    Customize your policy alerts

    Sign up for cpt 0630U policy alerts

    Get alerted when payer policies referencing 0630U are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Table of contents

    Progress1 / 7

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical & Coding Specifications

    Clinical Context

    A 55-year-old woman with early-stage invasive breast carcinoma undergoes lumpectomy with sentinel lymph node biopsy. Histopathology confirms estrogen receptor–positive tumor, and the treating oncologist requests molecular subtyping to refine prognosis and systemic therapy planning. A formalin-fixed paraffin-embedded (FFPE) tumor block from the surgical specimen is sent to Agendia® Inc. for the BluePrint® Molecular Subtyping Test. The laboratory performs mRNA gene expression profiling by microarray on the FFPE sample, evaluates an 80-gene panel, and uses a proprietary algorithm to generate a molecular subtype index (for example, luminal, basal, or HER2). The report is returned to the ordering clinician and incorporated into multidisciplinary treatment planning.

    Typical clinical workflow:

    • Clinician documents indication for molecular subtyping and places a lab order for the BluePrint® test.

    • Specimen processing staff selects an appropriate FFPE block and prepares slides/cores per lab submission requirements.

    • Sample is shipped to the performing laboratory (Agendia® Inc.) with required pathology report and order form.

    • The performing laboratory runs the proprietary microarray assay, interprets the algorithmic subtype index, and issues the test report.

    • The ordering clinician reviews the result and integrates the molecular subtype into prognosis discussion and therapeutic decision-making.

    Related CPT Codes

    CPT CodeDescriptionRelationship to This Procedure
    0630UBluePrint® Molecular Subtyping Test; mRNA gene expression profiling by microarray, 80 genes, algorithmic molecular subtype indexPrimary PLA code representing the proprietary assay performed by Agendia® Inc.
    88305Level IV surgical pathology, gross and microscopic examinationCommonly billed for histopathologic examination of the excised breast tumor prior to selection of FFPE block for molecular testing.
    88141Cytopathology, smears, single cell, using certain automated methods (example)May be used when cytologic samples are submitted for ancillary molecular testing (less common for BluePrint®).
    84999Unlisted chemistry procedureRarely used historically for novel assays before PLA assignment; now superseded by the PLA 0630U.
    99000Handling and/or conveyance of a specimen for transfer from elsewhere to the performing laboratory (example)Used by some facilities to bill specimen handling or courier services associated with sending FFPE blocks to reference labs.

    Related Modifiers

    5 rows

    ModifierDescriptionWhen to Use
    26Modifier 26 (Professional Component) identifies and bills only the professional portion of a split service — the physician’s interpretation, report, and medical judgment — when the technical…- Use CPT Modifier -26 when you are billing only the professional component (PC) of a split‑bill eligible service—i.e., you performed the physician interpretation, medical judgment and prepared a…
    90Modifier ‑90 (Reference/Outside Laboratory) indicates that a laboratory test was performed by an entity other than the treating or reporting provider. The American Medical Association defines…- Use CPT modifier -90 when a laboratory test is performed by an outside/reference laboratory (an entity other than the treating or reporting physician or qualified professional) and the claim needs…
    91Modifier 91 — “Repeat Clinical Diagnostic Laboratory Test” — is appended when the exact same CPT laboratory test is performed more than once for the same patient on the same day because serial,…- Use modifier 91 when the exact same CPT laboratory test is performed more than once on the same patient on the same date because serial or repeated testing is medically necessary to monitor…
    59Modifier 59 indicates a distinct procedural service when two procedures that are not normally billed together are clinically and procedurally separate. The CPT definition (as reiterated by CMS)…- Use modifier -59 to report a distinct procedural service when documentation supports that the procedure reported is not normally billed together with another service on the same day because of a…
    47Modifier -47 (“Anesthesia by Surgeon”) is appended to a surgical or procedural CPT code when the surgeon personally provides regional or general anesthesia for the procedure. Use of -47 indicates the…- Use modifier -47 when the surgeon personally provides regional or general anesthesia during the surgical procedure (i.e., the surgeon administers the anesthesia in addition to performing the…

    Related Provider Taxonomies

    8 rows

    Taxonomy Code
    207Q00000X
    207L00000X
    208000000X
    207K00000X
    207ZN0500X
    208G00000X
    163WH1000X
    335U00000X

    Related ICD-10-CM Codes

    24 rows

    ICD-10-CM CodeDescription
    C50.111Malignant neoplasm of central portion of right female breast
    C50.112Malignant neoplasm of central portion of left female breast
    C50.121Malignant neoplasm of central portion of right male breast
    C50.122Malignant neoplasm of central portion of left male breast
    C50.129Malignant neoplasm of central portion of unspecified male breast
    C50.211Malignant neoplasm of upper-inner quadrant of right female breast
    C50.212Malignant neoplasm of upper-inner quadrant of left female breast
    C50.219Malignant neoplasm of upper-inner quadrant of unspecified female breast
    C50.311Malignant neoplasm of lower-inner quadrant of right female breast
    C50.312Malignant neoplasm of lower-inner quadrant of left female breast

    Showing 1–10 of 24

    Related Payer Policy Updates

    Specialty: Genetic & Molecular Testing1 / 3

    10 rows

    PolicyPayerEffective Date
    Minimal Residual Disease (MRD) Testing for Cancerregence2027-01-01
    Biomarker Testing MandateBlue Cross Blue Shield - Rhode Island2027-01-01
    Prenatal (Fetal) Diagnostic TestingBlue Cross Blue Shield - Rhode Island2027-01-01
    Oral Cancer Screening and TestingOscar Health2027-01-01
    RTM Testing for Alpha-1 Antitrypsin DeficiencyOscar Health2027-01-01
    Cytochrome P450 Genotype-Guided Treatment Strategy Corporate Medical Policybcbsvermont2027-01-01
    Cytochrome P450 Genotypingblue cross blue shield - tennessee2026-12-31
    Polygenic Risk ScoreBlue Cross Blue Shield - Rhode Island2026-12-01
    Gene Expression Profiling for Cutaneous MelanomaBlue Cross Blue Shield - Rhode Island2026-12-01
    Chromosomal Microarray Testing for the Evaluation of Pregnancy Lossblue_shield_of_california2026-11-01

    Related Codes

    CPT-0001U-PRECISETYPE-HEA-MULTIPLEX-RBC-ANTIGEN-GENOTYPING

    CPT 0001U: PreciseType HEA Erythrocyte Antigen Genotyping

    CPT-0002U-POLYPDX-URINE-METABOLOMIC-ASSAY-ADENOMATOUS-POLYP-RISK

    CPT 0002U: PolypDX™ Urine Metabolomic Risk Assay

    CPT-0003U-OVAR-A-NEXT-GENERATION-OVARIAN-CANCER-RISK-ASSAY

    CPT 0003U: Overa (MIA2G) Ovarian Cancer Risk Assay

    CPT-0005U-PROSTATE-EXOSOMEDX-INTELLISCORE-GENE-EXPRESSION-URINE-TEST

    CPT 0005U: ExosomeDx Prostate (IntelliScore) urine gene expression test

    CPT-0007U-TOXPROTECT-URINE-DRUG-SCREEN-WITH-DNA-AUTHENTICATION

    CPT 0007U: ToxProtect Urine Drug Screen With DNA Authentication

    CPT-0008U-H-PYLORI-ANTIBIOTIC-RESISTANCE-SEQUENCING-PANEL

    CPT 0008U: H. pylori Antibiotic Resistance Gene Panel

    CPT-0009U-DEPARRAY-HER2-FISH-TUMOR-CELL-ISOLATION

    CPT 0009U: DEPArray HER2 Tumor‑Cell Isolation with FISH Analysis

    CPT-0010U-BACTERIAL-TYPING-WHOLE-GENOME-SEQUENCING-MAYO-CLINIC

    CPT 0010U: Bacterial Typing by Whole Genome Sequencing, Mayo Clinic

    CPT-0011U-CORDANT-CORE-ALGORITHMIC-ORAL-FLUID-DRUG-TEST

    CPT 0011U: Oral Fluid Drug Test with Algorithmic Steady‑State Comparison

    CPT-0016U-BCR-ABL1-MAJOR-MINOR-FUSION-TRANSCRIPT-TESTING

    CPT 0016U: BCR–ABL1 Major and Minor Breakpoint Fusion Transcripts

    Showing 1–10 of 536

    • More pages

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.